Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
January 24, 2026Journal of International Medical ResearchOpen Access

Mendelian randomization identifies multiple immune cell surface markers as potential causal contributors and drug targets in rheumatoid arthritis

View Full Paper
Ask AI
Bookmark
Share

Authors

GHGuangyu HuangYYYi YangGLGui Liao

Discussion

Loading...

Member takes

Overview

Mendelian randomization reveals immune cell surface markers as targets in rheumatoid arthritis, suggesting new treatment pathways.

Key Points

  • The aim is to identify immune cell phenotypes that causally contribute to rheumatoid arthritis and serve as potential drug targets.
  • Conducted Mendelian randomization using genome-wide association statistics from rheumatoid arthritis cohorts.
  • Analyzed immune cell traits to identify causal immune phenotypes.
  • Applied Bonferroni correction for multiple testing.
  • Utilized clinical trial evidence to validate therapeutic potential of identified targets.
  • Identified 92 nominally associated immune phenotypes in the discovery cohort, with 10 significant after correction.
  • Replication revealed 88 associations, with 4 significant after correction.
  • Meta-analysis suggested 17 phenotypes warranting further investigation.
  • Highlighted five immune markers (CD28, CD27, CX3CR1, CD3, HLA-DR) as promising drug targets.

Cite This Study

Huang et al. (2026) studied this question.

synapsesocial.com/papers/697461a8bb9d90c67120b851https://doi.org/10.1177/03000605251409686
View Full Paper
Ask AI
Bookmark
Share